07:00 , Sep 9, 2002 |  BC Week In Review  |  Company News

Oryx, Novartis deal

Specialty pharma company Oryx acquired Canadian rights to NVS's Anafranil clomipramine to treat depression and obsessive compulsive disorder, and Restoril temazepam for transient and short-term insomnia. The companies have an ongoing Canadian marketing deal for...
07:00 , Sep 3, 2002 |  BC Extra  |  Company News

Novartis, Oryx CNS deal

Specialty pharma company Oryx Pharmaceuticals (Mississauga, Ontario) acquired Canadian rights to Anafranil clomipramine from Novartis (NVS; SWX:NOVN) to treat depression and obsessive compulsive disease and Restoril temazepam for transient and short-term insomnia. The companies have...
08:00 , Dec 4, 2000 |  BC Week In Review  |  Company News

Cephalon, Novartis sales and marketing update

The companies formed a marketing collaboration in the U.K. covering five products to treat central nervous system (CNS) disorders. In addition to its Provigil modafinil for narcolepsy, CEPH will exclusively market in the U.K....
08:00 , Nov 27, 2000 |  BC Extra  |  Top Story

Cephalon in CNS deal with Novartis in U.K.

CEPH and Novartis (NVS; SWX:NOVN) established a marketing collaboration in the U.K. covering five products to treat central nervous system (CNS) disorders. CEPH will exclusively market four NVS products in the U.K.: Tegretol carbamazepine to...
07:00 , May 5, 1997 |  BioCentury  |  Strategy

How CoCensys plans life after Novartis

Finding opportunity in adversity is critical to running a sustainable company. CoCensys Inc. (COCN, Irvine, Calif.) is trying to do just that after partner Novartis Pharma AG (Basel, Switzerland) said it would drop development of...
08:00 , Nov 6, 1995 |  BioCentury  |  Strategy

CoCensys pushes into psychiatrics

CoCensys pushes into psychiatrics In a move that expands its CNS therapeutics portfolio from psychiatry into neurology, CoCensys Inc. struck a two-part collaboration with Warner-Lambert Co. and...
07:00 , Jul 18, 1994 |  BC Week In Review  |  Company News

CoCensys sales and marketing update

The Irvine, Calif., company said it will begin promoting its new line of central nervous system drugs on Aug. 1. In May, COCN, Ciba Pharmaceuticals and Ciba-Geigy Ltd. signed agreements under which COCN will co-promote...
07:00 , May 23, 1994 |  BioCentury  |  Strategy

Three-pronged COCN-Ciba deal

The deal between CoCensys and Ciba has three main elements: the co-development of Acea 1021; the building of a COCN sales force to co-promote four Ciba drugs; and the exercise by COCN of its option...